The View on GU | with Lalani and Wallis

There is currently a lack of organic multi-disciplinary discussion on what is truly impactful to the field of genitourinary (GU) cancers. The View on GU with Lalani and Wallis is a podcast that will integrate key clinical data from major conferences and high impact publications into meaningful take home messages for practicing clinicians. Importantly, Lalani and Wallis will also discuss the impact of governmental approvals and funding considerations on the GU oncology treatment landscape and provide practical considerations on the management of patients on new-to-market therapies.

The View on GU | with Lalani and Wallis is a health podcast hosted by Lalani, with 44 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Lalani hosts The View on GU | with Lalani and Wallis, a health show with 44 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #43

  Episode 43: ASCO Annual Meeting 2026 Commentary: Bladder Cancer

  Jun 5, 202630 minS0

  <p>Dr. Aly-Khan Lalani and Dr. Chris Wallis dive into the latest bladder cancer breakthroughs, starting with crucial long-term updates from the landmark EV-302 trial. They share encouraging survival data for patients, while exploring which treatments work best if the cancer eventually progresses. The doctors also discuss the future of localized disease, reviewing strategies from the POTOMAC and SAKK trials. By highlighting a range of advanced monitoring tools, they map out how modern care is helping patients safely avoid major surgery while maintaining excellent disease control.The View on GU with Lalani & Wallis integrates key clinical data from major conferences...

  ListenShow Notes
• 

  Episode #42

  Episode 42: ASCO Annual Meeting 2026 Commentary: Kidney Cancer

  Jun 5, 202625 minS0

  <p>Dr. Aly-Khan Lalani and Dr. Chris Wallis discuss how new data from the RAMPART trial strengthens the argument for administering  immune-boosting therapies to patients after surgery. This episode also touches on the human side of cancer care, exploring new ways to measure patient side effects and reduce post-treatment regret through improved  counseling. The doctors finish the conversation by highlighting a promising new combination of repurposed drugs that is offering renewed hope to young patients fighting Renal Medullary Carcinoma.</p><p>This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Me...

  ListenShow Notes
• 

  Episode #41

  Episode 41: ASCO Annual Meeting 2026 Commentary: Prostate Cancer

  Jun 5, 202635 minS0

  <p>Recorded in Chicago, Dr. Aly-Khan Lalani and Dr. Chris Wallis unpack a massive slate of prostate cancer data, fresh from the 2026 ASCO Annual Meeting. The conversation spans the entire disease spectrum, beginning with a deep dive into the PROTEUS trial. </p><p>Shifting to advanced disease, Dr. Lalani and Dr. Wallis discuss the TALAPRO-3 and the A-DREAM/Alliance A032101 trials. Concluding with a review of sequencing chemotherapy and radioligand therapy in the PLUDO trial, this episode provides an excellent overview of the prostate cancer landscape presented at ASCO 2026.</p><p>This podcast has been made possible through unrestricted financial s...

  ListenShow Notes
• 

  Episode #40

  Episode 40: Bladder Cancer Masterclass with Dr. Girish Kulkarni (Part 2)

  May 11, 202622 minS0

  <p>In Part 2 of the Bladder Cancer Awareness Month series, Dr. Kulkarni, Dr. Lalani and Dr. Wallis examine a "systemic therapy first" approach. Using a real-world patient scenario, the doctors break down the latest clinical trial data and discuss how the surge in neoadjuvant therapy is reshaping everyday decision-making.<br></p><p>The conversation also tackles the unique challenges of Upper Tract Urothelial Carcinoma. From evidence gaps in upper tract care to the complexities of trial design, this episode offers a forward-looking map of the evolving urothelial cancer landscape.</p><p>This podcast has been made possible through unrestricted financial...

  ListenShow Notes
• 

  Episode #39

  Episode 39: Bladder Cancer Masterclass with Dr. Girish Kulkarni (Part 1)

  May 11, 202629 minS0

  <p>From practical risk stratification to the real-world challenges of delivering BCG, Dr. Aly-Khan Lalani and Dr. Christopher Wallis lead a conversation with Dr. Kulkarni about non-muscle invasive bladder cancer and its rapidly evolving treatment landscape. </p><p>Dr. Kulkarni is a urologic surgeon at the Princess Margaret Cancer Centre, University Health Network, and a surgeon-scientist and Assistant Professor at the University of Toronto. As a thought leader in bladder cancer, he shares key clinical decision points, patient-centred considerations, and practical strategies that clinicians can apply today.</p><p>This podcast has been made possible through unrestricted financial support by J...

  ListenShow Notes

Recent guests on The View on GU | with Lalani and Wallis. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.